Stockreport

Appendix 4C – Q3 FY24 Quarterly Cash Flow Report

Alterity Therapeutics Limited - American Depositary Shares  (ATHE) 
PDF Highlights ATH434-201 Phase 2 baseline data confirm approach to target biomarkers for slowing disease progressionPresented promising nonclinical data on ATH434 in a pri [Read more]